PTX-100 is under clinical development by Prescient Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect PTX-100’s likelihood of approval (LoA) and phase transition for Peripheral T-Cell Lymphomas (PTCL) took place on 19 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PTX-100 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
PTX-100 (GGTI-2418) is under development for the treatment of angioimmunoblastic T-cell lymphoma (AITL), cutaneous T cell lymphoma, peripheral T-cell lymphoma, gastric cancer, solid tumours including multiple myeloma, pancreatic cancer and colorectal cancer. It is administered by intravenous route. The drug candidate is synthetic peptidomimetic which acts by targeting geranylgeranyltransferase I (GGTase I) and transforming protein RhoA. It was under development for the treatment of adult T-cell leukemia and lymphoma (ATL), Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), metastatic breast cancer and lung cancer.
Prescient Therapeutics overview
Prescient Therapeutics, formerly Virax Holdings, is a biotechnology company. It develops novel medicines for cancer treatment. The company is investigating OmniCAR, an immune receptor platform that controls T-cell activity and multi-antigen targeting with a single cell product for combined approach to formulate novel chimeric antigen receptor T (CAR-T) to treat cancer and other diseases. Its pipeline products include PTX-100, a compound which blocks geranylgeranyl transferase-1 (GGT-1), a cancer growth enzyme; and PTX-200, a novel PH domain inhibitor that obstructs protein kinase B or AKT signalling, which develops breast, ovarian cancer and leukemia. The company’s OmniCAR platform is built on technology licensed from University of Pennsylvania and SpyTag/SpyCatcher binding system licensed from Oxford University to develop improved CAR-T approaches for treating cancer and solid tumors. Prescient Therapeutics is headquartered in South Melbourne, Victoria, Australia.
Quick View PTX-100 LOA Data
|Highest Development Stage|